Journal Article
. 2008 Mar;21(10).
doi: 10.1038/modpathol.2008.54.

Histopathologic variables predict Oncotype DX recurrence score

Melina B Flanagan 1 David J Dabbs  Adam M Brufsky  Sushil Beriwal  Rohit Bhargava  
Affiliations
  • PMID: 18360352
  •     63 citations

Abstract

Oncotype DX is a commercially available reverse transcriptase-polymerase chain reaction based assay that provides a Recurrence Score (RS) and has been shown to provide prognostic and predictive information in estrogen receptor-positive lymph node-negative breast cancers. Independent studies of its utility in routine practice are lacking. Slides and surgical pathology reports from 42 cases of breast carcinomas evaluated by Oncotype DX were retrospectively reviewed to determine patient age, tumor size, histologic grade, estrogen and progesterone receptor (ER and PR) and ERBB2 (HER-2/neu) data, with ER and PR reported as a semi-quantitative score reflecting both intensity of staining and proportion of positive cells. We show here that Recurrence Score is significantly correlated with tubule formation, nuclear grade, mitotic count, ER immunohistochemical score, PR immunohistochemical score, and HER-2/neu status, and that the equation RS=13.424+5.420 (nuclear grade) +5.538 (mitotic count) -0.045 (ER immunohistochemical score) -0.030 (PR immunohistochemical score) +9.486 (HER-2/neu) predicts the Recurrence Score with an R2 of 0.66, indicating that the full model accounts for 66% of the data variability. Although the Oncotype DX Recurrence Score holds potential, further validation of its independent value beyond that of histopathologic analysis is necessary before it can be implemented in clinical decision making.

Luminal B breast tumors are not HER2 positive.
Rohit Bhargava, David J Dabbs.
Breast Cancer Res, 2008 Oct 04; 10(5). PMID: 18831725    Free PMC article.
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
Andrew Tutt, Alice Wang, +21 authors, Fred Waldman.
BMC Cancer, 2008 Nov 26; 8. PMID: 19025599    Free PMC article.
Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers.
Rohit Bhargava, Joan Striebel, +4 authors, David J Dabbs.
Int J Clin Exp Pathol, 2009 Mar 19; 2(5). PMID: 19294003    Free PMC article.
Cryotherapy for breast cancer: a feasibility study without excision.
Peter J Littrup, Bassel Jallad, +3 authors, David Bouwman.
J Vasc Interv Radiol, 2009 Oct 06; 20(10). PMID: 19800542    Free PMC article.
[Beyond staging, typing and grading. New challenges in breast cancer pathology].
H H Kreipe, P Ahrens, +2 authors, F Länger.
Pathologe, 2009 Dec 02; 31(1). PMID: 19949797
Review.
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
S Sahebjam, R Aloyz, +6 authors, L C Panasci.
Br J Cancer, 2011 Oct 06; 105(9). PMID: 21970880    Free PMC article.
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Jennifer E Joh, Nicole N Esposito, +10 authors, Geza Acs.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016474    Free PMC article.
Impact of multigene assays in early stage breast cancer.
Shelly S Lo, Kathy S Albain.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016475    Free PMC article.
Toward deciphering proteomes of formalin-fixed paraffin-embedded (FFPE) tissues.
Sameh Magdeldin, Tadashi Yamamoto.
Proteomics, 2012 Feb 10; 12(7). PMID: 22318899    Free PMC article.
Review.
Membrane progesterone receptor alpha as a potential prognostic biomarker for breast cancer survival: a retrospective study.
Mingxuan Xie, Xiangzhu Zhu, +6 authors, Shaojin You.
PLoS One, 2012 Apr 13; 7(4). PMID: 22496908    Free PMC article.
Multi-field-of-view strategy for image-based outcome prediction of multi-parametric estrogen receptor-positive breast cancer histopathology: Comparison to Oncotype DX.
Ajay Basavanhally, Michael Feldman, +4 authors, Anant Madabhushi.
J Pathol Inform, 2011 Jan 01; 2. PMID: 22811953    Free PMC article.
Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.
Malek B Hannouf, Bin Xie, Muriel Brackstone, Gregory S Zaric.
BMC Cancer, 2012 Oct 04; 12. PMID: 23031196    Free PMC article.
[Translational research and diagnostics for breast cancer].
H H Kreipe.
Pathologe, 2012 Oct 16; 33 Suppl 2. PMID: 23064514
Review.
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat.
Ont Health Technol Assess Ser, 2010 Jan 01; 10(23). PMID: 23074401    Free PMC article.
A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer.
Qingchao Qiu, Pengcheng Lu, +6 authors, Yajun Yi.
PLoS One, 2013 Feb 06; 8(1). PMID: 23383020    Free PMC article.
Multi-field-of-view framework for distinguishing tumor grade in ER+ breast cancer from entire histopathology slides.
Ajay Basavanhally, Shridar Ganesan, +4 authors, Anant Madabhushi.
IEEE Trans Biomed Eng, 2013 Feb 09; 60(8). PMID: 23392336    Free PMC article.
Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
Molly E Klein, David J Dabbs, +4 authors, Rohit Bhargava.
Mod Pathol, 2013 Mar 19; 26(5). PMID: 23503643    Free PMC article.
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
Zsuzsanna Varga, Peter Sinn, +6 authors, Holger Moch.
PLoS One, 2013 Mar 19; 8(3). PMID: 23505515    Free PMC article.
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, +19 authors, College of American Pathologists.
Arch Pathol Lab Med, 2013 Oct 09; 138(2). PMID: 24099077    Free PMC article.
Highly Cited.
Filamin A expression correlates with proliferation and invasive properties of human metastatic melanoma tumors: implications for survival in patients.
Kai Zhang, Tienian Zhu, +6 authors, Ruijing Zhao.
J Cancer Res Clin Oncol, 2014 Jun 09; 140(11). PMID: 24908328
The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea.
Moo Hyun Lee, Wonshik Han, +7 authors, Eun Sook Lee.
Cancer Res Treat, 2014 Nov 11; 47(2). PMID: 25381828    Free PMC article.
Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.
Elizabeth J Sutton, Jung Hun Oh, +5 authors, Elizabeth A Morris.
J Magn Reson Imaging, 2015 Apr 09; 42(5). PMID: 25850931    Free PMC article.
Highly Cited.
Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Brian David Lehmann, Yan Ding, +6 authors, Yajun Yi.
BMC Cancer, 2015 Apr 18; 15. PMID: 25886164    Free PMC article.
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Bradley M Turner, Kristin A Skinner, +6 authors, David G Hicks.
Mod Pathol, 2015 May 02; 28(7). PMID: 25932962
A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.
Michele M Gage, Martin Rosman, +6 authors, Lorraine Tafra.
Clin Breast Cancer, 2015 Jun 15; 15(6). PMID: 26072275    Free PMC article.
Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience.
E Baxter, L Gondara, +5 authors, S Tyldesley.
Curr Oncol, 2015 Jun 20; 22(3). PMID: 26089718    Free PMC article.
Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival.
Se Kyung Lee, Soo Youn Bae, +6 authors, Seok Jin Nam.
PLoS One, 2015 Aug 05; 10(8). PMID: 26241661    Free PMC article.
Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer.
Lik Hang Lee, Paul E Swanson, +2 authors, Hua Yang.
Appl Immunohistochem Mol Morphol, 2015 Sep 16; 25(1). PMID: 26371428    Free PMC article.
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.
Anton Safonov, Shiyi Wang, +4 authors, Christos Hatzis.
Breast Cancer Res Treat, 2016 Jan 11; 155(2). PMID: 26749360    Free PMC article.
Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score.
Thaer Khoury, Xiao Huang, +3 authors, Mateusz Opyrchal.
Appl Immunohistochem Mol Morphol, 2016 Jan 26; 24(10). PMID: 26808126    Free PMC article.
Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey.
Vahit Ozmen, Ajlan Atasoy, +7 authors, Pinar Saip.
Cureus, 2016 Apr 16; 8(3). PMID: 27081583    Free PMC article.
Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Su Hyun Lee, Seunggyun Ha, +9 authors, Gi Jeong Cheon.
Eur J Nucl Med Mol Imaging, 2016 May 23; 43(9). PMID: 27209424
Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features.
Huaidong Chen, Wei Chen, +3 authors, Xiaobo Zhou.
Sci Rep, 2016 Jul 19; 6. PMID: 27427091    Free PMC article.
Automated Tubule Nuclei Quantification and Correlation with Oncotype DX risk categories in ER+ Breast Cancer Whole Slide Images.
David Romo-Bucheli, Andrew Janowczyk, +2 authors, Anant Madabhushi.
Sci Rep, 2016 Sep 08; 6. PMID: 27599752    Free PMC article.
Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
Hyun-Seok Kim, Christopher B Umbricht, +22 authors, Leslie Cope.
J Clin Oncol, 2016 Dec 22; 34(36). PMID: 27998227    Free PMC article.
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Michael R Harowicz, Timothy J Robinson, +4 authors, Maciej A Mazurowski.
Breast Cancer Res Treat, 2017 Jan 09; 162(1). PMID: 28064383    Free PMC article.
A deep learning based strategy for identifying and associating mitotic activity with gene expression derived risk categories in estrogen receptor positive breast cancers.
David Romo-Bucheli, Andrew Janowczyk, +2 authors, Anant Madabhushi.
Cytometry A, 2017 Feb 14; 91(6). PMID: 28192639    Free PMC article.
Proteomic Analysis of Matched Formalin-Fixed, Paraffin-Embedded Specimens in Patients with Advanced Serous Ovarian Carcinoma.
Ashlee L Smith, Mai Sun, +7 authors, Kristin K Zorn.
Proteomes, 2013 Oct 17; 1(3). PMID: 28250404    Free PMC article.
Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey.
Vahit Özmen, Ajlan Atasoy, +9 authors, Pınar Saip.
J Breast Health, 2016 Jan 01; 12(3). PMID: 28331745    Free PMC article.
21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.
Julie A Lynch, Brygida Berse, Nicole Coomer, John Kautter.
Genet Med, 2017 Mar 24; 19(10). PMID: 28333918
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.
Daniel J Farrugia, Alessandra Landmann, +13 authors, Rohit Bhargava.
Mod Pathol, 2017 May 27; 30(8). PMID: 28548119
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Gulisa Turashvili, Edi Brogi, +4 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2017 Jun 04; 165(1). PMID: 28577081    Free PMC article.
Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer.
Maura Bríd Cotter, Alex Dakin, +5 authors, Cecily M Quinn.
Virchows Arch, 2017 Jul 15; 471(3). PMID: 28707056
Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.
Chieh-Yu Lin, Kelly Mooney, +5 authors, Kimberly Allison.
Mod Pathol, 2017 Dec 16; 31(4). PMID: 29243740
The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
Satbir Singh Thakur, Haocheng Li, +5 authors, Hua Yang.
PLoS One, 2018 Jan 06; 13(1). PMID: 29304138    Free PMC article.
Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
M M Gage, W C Mylander, +9 authors, R S Jackson.
Ann Oncol, 2018 May 23; 29(5). PMID: 29788166    Free PMC article.
Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
Jon Whitney, German Corredor, +6 authors, Anant Madabhushi.
BMC Cancer, 2018 Jun 01; 18(1). PMID: 29848291    Free PMC article.
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?
Giuseppe Bronte, Sara Bravaccini, +12 authors, Andrea Rocca.
Transl Oncol, 2018 Jun 12; 11(4). PMID: 29890379    Free PMC article.
Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center.
Hans-Ullrich Voelker, Lea Frey, Annette Strehl, Michael Weigel.
Int J Breast Cancer, 2018 Aug 17; 2018. PMID: 30112216    Free PMC article.
Evaluation of the predictive ability of ultrasound-based assessment of breast cancer using BI-RADS natural language reporting against commercial transcriptome-based tests.
Neema Jamshidii, Jason Chang, +3 authors, Michael D Kuo.
PLoS One, 2020 Jan 11; 15(1). PMID: 31923222    Free PMC article.
Breast Cancers With Magee Equation Score of Less Than 18, or 18-25 and Mitosis Score of 1, Do Not Require Oncotype DX Testing: A Value Study.
Rohit Bhargava, Beth Z Clark, David J Dabbs.
Am J Clin Pathol, 2018 Nov 06; 151(3). PMID: 30395177    Free PMC article.
Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system.
Esther C Yoon, Christopher Schwartz, +3 authors, Farbod Darvishian.
Breast J, 2019 Jun 15; 25(5). PMID: 31197914    Free PMC article.
Introduction to digital pathology and computer-aided pathology.
Soojeong Nam, Yosep Chong, +5 authors, Heounjeong Go.
J Pathol Transl Med, 2020 Feb 13; 54(2). PMID: 32045965    Free PMC article.
Review.
The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer.
Atilla Soran, Kaori Tane, Efe Sezgin, Rohit Bhargava.
Eur J Breast Health, 2020 Apr 15; 16(2). PMID: 32285033    Free PMC article.
The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Napat Saigosoom, Doonyapat Sa-Nguanraksa, +2 authors, Pornchai O-Charoenrat.
Cancer Manag Res, 2020 Apr 21; 12. PMID: 32308485    Free PMC article.
Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls.
Joseph Liu, Anupama Suresh, +18 authors, Robert Wesolowski.
Eur J Breast Health, 2020 Jul 14; 16(3). PMID: 32656521    Free PMC article.
The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer.
Rohit Bhargava, Beth Z Clark, +2 authors, David J Dabbs.
Mod Pathol, 2020 Mar 24; 33(8). PMID: 32203092    Free PMC article.
Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.
Sreeja Sreekumar, Kevin M Levine, +12 authors, Steffi Oesterreich.
Endocrinology, 2020 Jul 02; 161(9). PMID: 32609836    Free PMC article.
BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score.
Mark D Zarella, Rebecca C Heintzelman, Nikolay K Popnikolov, Fernando U Garcia.
BMC Clin Pathol, 2018 Dec 24; 18. PMID: 30574014    Free PMC article.
Introduction to Digital Image Analysis in Whole-slide Imaging: A White Paper from the Digital Pathology Association.
Famke Aeffner, Mark D Zarella, +11 authors, Douglas Bowman.
J Pathol Inform, 2019 Apr 16; 10. PMID: 30984469    Free PMC article.
Highly Cited. Review.
Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients.
Hazem I Assi, Ibrahim A Alameh, +9 authors, Nagi El Saghir.
J Oncol, 2020 Dec 15; 2020. PMID: 33312202    Free PMC article.
Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer.
Abdulmohsen Alkushi, Ahmad Omair, +2 authors, Omalkhair Abualkhair.
Breast Cancer (Auckl), 2020 Dec 22; 14. PMID: 33343196    Free PMC article.
Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.
Rohit Bhargava, Nicole N Esposito, +11 authors, David J Dabbs.
Mod Pathol, 2020 Jul 15; 34(1). PMID: 32661297